MYDERM
MYDERM is developed from a small biopsy of healthy skin harvested from the patient, further processed to isolate skin cells (keratinocytes and fibroblast cells). The cells are expanded in vitro and then used in combination with a fibrin matrix to create a 3D bilayer skin construct, ready to be transplanted on wounds.
MYDERM works by covering the surface of the wound and acts as an organ transplant with live cells that will assimilate and integrate with the patient's own body and skin. |
CELLTIGRAFT
CELLTIGRAFT is an Autologous Bilayer Tissue Engineered Human Skin (TEHS) used to treat and manage skin loss injuries and wounds. It is completely compatible with patients, with zero chance of rejection.
CELLTIGRAFT is constructed of 1 to 2 million fibroblast and keratinocyte cells which are embedded in human plasma. |
ALGRAFTALGRAFT is an Allogenic Bilayer Tissue Engineered Human Skin (TEHS) substitute used to treat and manage wounds and major skin loss. It is derived from young, healthy donors who have gone through extensive screening before extraction, amplification, and construction as TEHS. It comprises fibroblast and keratinocyte cells that mimic 90% of human skin morphology and functions.
ALGRAFT is beneficial for early coverage of wounds to prevent infection, contracture, and promote healing by stimulating the patient's skin formation. |
CELL TISSUE TECHNOLOGY SDN BHD
Malaysia's FIRST Tissue Engineering Firm |
|